Skip to main content

Advertisement

SpringerLink
Log in

Reversal of Hepatic Dysfunction After Exceptional Responses to Lenvatinib

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data Availability

All data generated or analysed during this study are included in this article.

References

  1. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma Nat Rev Dis Primers. 2021;7:6.

    Article  PubMed  Google Scholar 

  2. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-50.

    Article  PubMed  Google Scholar 

  3. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.

    Article  CAS  PubMed  Google Scholar 

  4. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

    Article  CAS  PubMed  Google Scholar 

  5. Kondo T, Koroki K, Kanzaki H, et al. Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma. PLoS One. 2022;17.

  6. Hung HH, Chao Y, Chiou YY, et al. A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and child-pugh scores of 5 or 6. Medicine (Baltimore). 2014;93:e348.

  7. Bunchorntavakul C, Reddy KR. Treat chronic hepatitis c virus infection in decompensated cirrhosis - pre- or post-liver transplantation? The ironic conundrum in the era of effective and well-tolerated therapy. J Viral Hepat. 2016;23:408–18.

    Article  CAS  PubMed  Google Scholar 

  8. Shek D, Read SA, Nagrial A, et al. Immune-checkpoint inhibitors for advanced hepatocellular carcinoma: a synopsis of response rates. Oncologist. 2021;26:e1216–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas Southwestern Medical School, Dallas, TX, 75390, USA

    Maishara Muquith

  2. Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA

    Magdalena Espinoza

  3. Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA

    David Hsiehchen

Authors
  1. Maishara Muquith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Magdalena Espinoza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Hsiehchen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Maishara Muquith, Magdalena Espinoza, and David Hsiehchen participated in data analysis and writing of the manuscript.

Corresponding author

Correspondence to David Hsiehchen.

Ethics declarations

Ethics Approval

Ethical approval is not required for this study in accordance with local or national guidelines. Written informed consent was obtained from patients to include clinical data in this publication.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Muquith, M., Espinoza, M. & Hsiehchen, D. Reversal of Hepatic Dysfunction After Exceptional Responses to Lenvatinib. J Gastrointest Canc 54, 982–985 (2023). https://doi.org/10.1007/s12029-022-00852-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-022-00852-w

Keywords

Search

Navigation